BillionToOne, Inc. (BLLN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

131.2x

EV/EBITDA

85.3x

Market Cap

$4.69B

MomentumView details →

1D Return

−0.11%

YTD Return

+20.94%

RSI (14)

46.9

ValuationView details →

P/E (Fwd)

131.2x

EV/EBITDA

85.3x

Market Cap

$4.69B

RSI (14)

46.9

MomentumView details →

1D Return

−0.11%

YTD Return

+20.94%

ProfitabilityView details →

Gross Margin

71.27%

Net Margin

8.43%

EBITDA Margin

12.64%

ROE (TTM)

6.24%

ROA (TTM)

4.59%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

+90.12%

EPS YoY

+200.79%

FCF YoY

—

Revenue CAGR 3Y

+106.24%

EPS CAGR 3Y

+106.85%

EBITDA YoY

+320.49%

EarningsView details →

EPS (Actual)

$0.15

EPS Surprise

−18.17%

Beats (12Q)

2/12

Next Q EPS Est

$0.15

Avg Surprise (4Q)

248.11%

Rev Surprise

0.17%

Capital & dividendView details →

Debt/Equity

0.27x

Current Ratio

11.69x

Quick Ratio

11.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

397.41M

Net Income (TTM)

33.51M

Op. CF (TTM)

45.35M

Next earningsOct 6, 2026 →

Latest newsMore news →

BillionToOne launched Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, and expanded its Northstar Select panel from 84 to 102 genes.3d ago

Billiontoone reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses, and posted positive operating income and free cash flow.30d ago

Similar companies

Sotera Health CompanySHC 润达医疗603108.SH RadNet, Inc.RDNT GRAIL, Inc.GRAL 塞力医疗603716.SH Adicon Holdings Limited09860.HK Find similar companies →

Latest newsMore news →

BillionToOne launched Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, and expanded its Northstar Select panel from 84 to 102 genes.3d ago Billiontoone reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses, and posted positive operating income and free cash flow.30d ago